Pantherna Therapeutics presented at the RNA Therapeutics Conference in London, UK.
Dr. Klaus Giese provided an outline of Pantherna’s therapeutic programs how to tackle vascular leakage in the lung caused by viral infection i.e. Corona virus (SARS-CoV-2) and Influenza.
Pantherna Therapeutics to present at BIO-Europe 2019
Dr. Klaus Giese (CEO) will present in the Start-Up Slam at the BIO-Europe 2019 conference in Hamburg on Tuesday, Nov 12.
Pantherna Therapeutics to present at mRNA Health Conference 2019
Dr. Daniel Tondera and Dr. Jörg Kaufmann (CSO) will attend and present a poster at the 7th International mRNA Health Conference, November 11-12, 2019, in Berlin, Germany
Pantherna Therapeutics to present at the Creative Transformative Medicine Europe User Group Meeting
Dr. Oliver Keil (CTO), Dr. Volker Fehring (Head of Formulation) and Dr. Klaus Giese (CEO) will attend the Creative Transformative Medicine Europe User Group Meeting to be held at the University of Strathclyde, Glasgow, on [...]
“First-in-Class“ mRNA-therapeutics for vascular diseases: Pantherna Therapeutics receives 7-digit investment
The life science start-up Pantherna Therapeutics secures €3.5 million in a successful seedfinancing round. The start-up presents a proprietary, innovative technology platform for the development of novel mRNA therapeutics to treat Acute Respiratory Distress Syndrome [...]
Pantherna Therapeutics participated as a finalist at BioRiver Boost! 2018 in Wuppertal.
The Company was presented by Dr. Klaus Giese, Chief Executive Officer, in a pitch session of selected finalists and Pantherna’s technology & business case was awarded a joint second place.
Pantherna Therapeutics presented at the RNA Therapeutics Conference in London, UK.
Dr. Klaus Giese provided an outline of Pantherna’s therapeutic programs how to tackle vascular leakage in the lung caused by viral infection i.e. Corona virus (SARS-CoV-2) and Influenza.
Pantherna Therapeutics to present at BIO-Europe 2019
Dr. Klaus Giese (CEO) will present in the Start-Up Slam at the BIO-Europe 2019 conference in Hamburg on Tuesday, Nov 12.
Pantherna Therapeutics to present at mRNA Health Conference 2019
Dr. Daniel Tondera and Dr. Jörg Kaufmann (CSO) will attend and present a poster at the 7th International mRNA Health Conference, November 11-12, 2019, in Berlin, Germany
Pantherna Therapeutics to present at the Creative Transformative Medicine Europe User Group Meeting
Dr. Oliver Keil (CTO), Dr. Volker Fehring (Head of Formulation) and Dr. Klaus Giese (CEO) will attend the Creative Transformative Medicine Europe User Group Meeting to be held at the University of Strathclyde, Glasgow, on [...]
“First-in-Class“ mRNA-therapeutics for vascular diseases: Pantherna Therapeutics receives 7-digit investment
The life science start-up Pantherna Therapeutics secures €3.5 million in a successful seedfinancing round. The start-up presents a proprietary, innovative technology platform for the development of novel mRNA therapeutics to treat Acute Respiratory Distress Syndrome [...]
Pantherna Therapeutics participated as a finalist at BioRiver Boost! 2018 in Wuppertal.
The Company was presented by Dr. Klaus Giese, Chief Executive Officer, in a pitch session of selected finalists and Pantherna’s technology & business case was awarded a joint second place.
Pantherna Therapeutics filed its first patent application “Recombinant nucleic acid construct”.
The patent filing of our ideas with confirming experimental data is a first milestone and signals an inflection point for Pantherna said Dr. Jörg Kaufmann, Chief Scientific Officer. “Now we can openly communicate Pantherna’s R&D strategy [...]
Pantherna Therapeutics presented at Biovaria in Munich.
Dr. Klaus Giese, Pantherna’s CEO, provided an overview of the Company’s R&D strategy.
Pantherna Therapeutics contracted with the Institute of Biomaterial Research of the Helmholtz-Zentrum Geesthacht.
Under this contract the Institute will generate and functionally evaluate mRNA constructs designed by Pantherna.
Pantherna Therapeutics attended the BIO.NRW Business Angel ZIRKEL in Duesseldorf.
Dr. Gerrit Maaß, Chief Financial Officer, and Dr. Klaus Giese, Chief Executive Officer, were invited to outline the Company’s future strategy to develop mRNA-based therapeutics (PanRNA Therapeutics) for vascular diseases.
Dr. Oliver Keil joined Pantherna Therapeutics as Chief Technology Officer.
Oliver is an experienced chemist with a long standing list of achievements in the field of drug delivery technologies, including the supervision of several CMC campaigns with liposomal-based nucleic acid inhibitors at Silence Therapeutics. His [...]
Pantherna Therapeutics presented at the RNA Therapeutics Conference in London, UK.
Dr. Klaus Giese provided an outline of Pantherna’s therapeutic programs how to tackle vascular leakage in the lung caused by viral infection i.e. Corona virus (SARS-CoV-2) and Influenza.
Pantherna Therapeutics to present at BIO-Europe 2019
Dr. Klaus Giese (CEO) will present in the Start-Up Slam at the BIO-Europe 2019 conference in Hamburg on Tuesday, Nov 12.
Pantherna Therapeutics to present at mRNA Health Conference 2019
Dr. Daniel Tondera and Dr. Jörg Kaufmann (CSO) will attend and present a poster at the 7th International mRNA Health Conference, November 11-12, 2019, in Berlin, Germany
Pantherna Therapeutics to present at the Creative Transformative Medicine Europe User Group Meeting
Dr. Oliver Keil (CTO), Dr. Volker Fehring (Head of Formulation) and Dr. Klaus Giese (CEO) will attend the Creative Transformative Medicine Europe User Group Meeting to be held at the University of Strathclyde, Glasgow, on [...]
“First-in-Class“ mRNA-therapeutics for vascular diseases: Pantherna Therapeutics receives 7-digit investment
The life science start-up Pantherna Therapeutics secures €3.5 million in a successful seedfinancing round. The start-up presents a proprietary, innovative technology platform for the development of novel mRNA therapeutics to treat Acute Respiratory Distress Syndrome [...]
Pantherna Therapeutics participated as a finalist at BioRiver Boost! 2018 in Wuppertal.
The Company was presented by Dr. Klaus Giese, Chief Executive Officer, in a pitch session of selected finalists and Pantherna’s technology & business case was awarded a joint second place.
Pantherna Therapeutics filed its first patent application “Recombinant nucleic acid construct”.
The patent filing of our ideas with confirming experimental data is a first milestone and signals an inflection point for Pantherna said Dr. Jörg Kaufmann, Chief Scientific Officer. “Now we can openly communicate Pantherna’s R&D strategy [...]
Pantherna Therapeutics presented at Biovaria in Munich.
Dr. Klaus Giese, Pantherna’s CEO, provided an overview of the Company’s R&D strategy.
Pantherna Therapeutics contracted with the Institute of Biomaterial Research of the Helmholtz-Zentrum Geesthacht.
Under this contract the Institute will generate and functionally evaluate mRNA constructs designed by Pantherna.
Pantherna Therapeutics attended the BIO.NRW Business Angel ZIRKEL in Duesseldorf.
Dr. Gerrit Maaß, Chief Financial Officer, and Dr. Klaus Giese, Chief Executive Officer, were invited to outline the Company’s future strategy to develop mRNA-based therapeutics (PanRNA Therapeutics) for vascular diseases.
Dr. Oliver Keil joined Pantherna Therapeutics as Chief Technology Officer.
Oliver is an experienced chemist with a long standing list of achievements in the field of drug delivery technologies, including the supervision of several CMC campaigns with liposomal-based nucleic acid inhibitors at Silence Therapeutics. His [...]